Skip to main content
SpringerLink
Log in

Plasma Lipids and Frequency of Hyperlipidaemia in the Elderly: Indications and Cost/Benefit Ratio of Hypolipidaemic Treatment

  • Chapter
Aging and Drug Therapy

Part of the book series: Ettore Majorana International Science Series ((PSLI))

  • 81 Accesses

Abstract

In recent years substantial progress in the study of atherosclerosis has led to the definition of some now well known risk factors, and hence to the possibility of carrying out realistic programs of prevention and therapy. These risk factors include the hyperlipaemias, common metabolic disorders of the plasma lipoproteins which may be primary with genetic origins, or secondary to endocrine disease, organic disease, drug therapy, or dietary habits. The interest in these alterations, however, has mostly been focused on the young and middle age groups, overlooking the elder age groups (Kritchevsky).1 Moreover, the data supplied by the Lipid Research Clinic Programs of the National Heart, Lung, and Blood Institute (U.S.A.) refer to plasma lipid values for age and sex for quinguennial groups, but only up to 70 years of age. 2 Nonetheless, the increase in the population of elderly persons, which has been recorded in these years, and the consequent growth of geriatric pathology, raise, among others, the problem of defining the metabolic alterations present in this age group, and among these, the dyslipidaemias.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. D. Kritchevsky, How aging affects cholesterol metabolism,Post-grad Med. 63: 133 (1978)

    Google Scholar 

  2. R. J. Havel, Symposium on Lipid Disorders,Med.Clinics N.Amer 66: 319 (1982)

    Google Scholar 

  3. P. D. S. Wood, M. P. tern, A. Silvers, G. M. Reaven and J. von der Groeben, Prevalence of Plasma Lipoprotein Abnormalities in a free-living population of the Central Valley, California,Circulation 45: 114 (1972)

    Google Scholar 

  4. M. Werner, R. E. Tolls, and J. V. Hultin, Influence of sex and age on the normal range of eleven serum constituents,J.Clin.Chem.Clin.Biochem 8: 105 (1970)

    Google Scholar 

  5. A. Woldow, Hyperlipidemia and its significance in the aged population,J.Amer.Geriat.Soc 23: 407 (1975)

    Google Scholar 

  6. I. Harrill, C. Jansen, and J. Barthrop, Serum cholesterol and triglycerides and hyperlipoproteinemia in elderly women,J. Gerontol 33: 347 (1978)

    Google Scholar 

  7. M. S. Greenfield, F. Kraemer, T. Tobey, and G. Reaven, Effect of age on plasma triglyceride concentrations,in: “Man. Metabolism,” 29:1095 (1980)

    Google Scholar 

  8. R. Fellin, F. Bellavere, E. Manzato, G. Briani, G. Baldo, and MR. Baiocchi, Aspetti del metabolismo nel vecchio, Estratto dagli Atti del XXIII Congresso Nazionale Trieste, 27-29 Setembre 1976, Giorn Gerontol. Suppl LIX: 74 (1976)

    Google Scholar 

  9. M. Kekki, Plasma triglyceride turnover in 92 adult normolipaemic and 30 hypertriglyceridaemic subjects - the effect of age, synthesis rate and removal capacity on plasma triglyceride concentration, Ann.Clin.Research 12:.64 (1980).

    Google Scholar 

  10. G. M. Reaven, Effect of age and sex on triglyceride metabolism in the rat,J.Gerontol 33: 368 (1978)

    Google Scholar 

  11. S. Matter, B. A. Stamford, and A. Weltman, Age, diet, maximal aerobic capacity and serum lipids, J.Gerontol. 35: 532 (1980)

    Google Scholar 

  12. M. Sykes, W. M. Cnoop-Koopmans, P. Julien, and A. Angel, The effects of hypothyroidism, age, and nutrition on LDL catabolism in the rat,Metabolism 30:733 (1981)

    Google Scholar 

  13. C. J. Glueck, P. S. Gartside, P. M. Steiner, M. Miller, T. Todhunter, J. Haaf, M. Pucke, M. Terrana, R. W. Fallat, and M. L. Kashyap, Hyperalpha- and hypobeta- lipoproteinemai in octogenarian kindreds,Atherosclerosis 27: 387 (1977)

    Article  Google Scholar 

  14. H. Heckers, W. Burkard, F. W. Schmahl, W. Fuhrmann, and D. Platt, Hyper-alpha-lipoproteinemia and hypo-beta-lipoproteinemia are: not markers for a high life expectancy–Serum lipid and lipoprotein findings in 103 randemly selected nonagenarians,Gerontology 28: 176 (1982)

    Article  Google Scholar 

  15. J. Horsey, B. Livesley, and J. W. T. Dickerson, Aged men and ischaemic heart disease: Serum cholesterol and triglyceride levels,Age and Ageing 9: 154 (1980)

    Article  Google Scholar 

  16. J. L. Goldstein, and M. S. Brown, in: “Harrison’s Principles of Internal Medicine,” 407 IX edition, McGraw Hill (1980)

    Google Scholar 

  17. W. B. Kannell, W. P. Castelli, T. Gordon, and P. M. McNamara, Serum cholesterol, lipoproteins, and the risk of coronary heart disease,Ann.Intern.Med. 74: 1 (1971)

    Google Scholar 

  18. F. H. Epstein, Epidemiologic aspects of atherosclerosis,Atherosclerosis 14: 1 (1971)

    Article  Google Scholar 

  19. H. J. Albrink, J. W: Meigs, and E. B. Man, Serum Lipids, hypertension, and coronary artery disease,Am.J.Med. 31: 4 (1961)

    Article  Google Scholar 

  20. L. A. Carlson, and L. E. Bottiger, Ischaemic heart disease in relation to fasting values of plasma triglycerides and cholesterol,Lancet 1: 865 (1972)

    Article  Google Scholar 

  21. R. Jr. Barndt, D. H. Blankenhorn, D. W. Crawford, and S.H. Brooks, Regression and progression of early femoral atherosclerosis in treated hyperlipoproteinemic patients,Ann.Intern.Med. 86: 139 (1977)

    Google Scholar 

  22. The Scottish Study (1971),.A secondary prevention trial using clofibrate, Research Committee in: “The Scottish Society of Physicians,”Brit. med. J.4:775 (1971):

    Google Scholar 

  23. The Newcastle Study, Trial of clofibrate in the treatment of ischaemic heart disease, (Physicians of the Newcastle upon Tyne Region) Brit.Med.J 4: 767 (1971)

    Article  Google Scholar 

  24. Coronary Drug Project Research Group, Clofibrate and niacin in coronary heart disease,J.Amer.Med.Assoc 231: 360 (1975)

    Article  Google Scholar 

  25. Coronary Drug Project Research Group, Findings leading to discontinuation of the 2.5 mg/day estrogen group,J.Amer.Med.Assoc 226: 652 (1973)

    Article  Google Scholar 

  26. Coronary Drug Project Research Group, The coronary drug project: findings leading to further modifications of its protocol with respect to dextrotyroxine,J.Amer.Med.Assoc 220: 996 (1972)

    Article  Google Scholar 

  27. L. R. Krasno, and G. J. Kidera, Clofibrate in coronary heart disease, J.Amer.Med.Assoc. 219: 845 (1972)

    Article  Google Scholar 

  28. M. F. Oliver, J. A. Heady, J. N. Morris,and J. Cooper, A cooperative trial in the primary prevention of ischaemic heart disease using clofibrate, Brit.Heart J. 40: 1069 (1978)

    Google Scholar 

  29. A. E. Dorr, K. Gundersen, J. C. Schneider, T. W. Sprencer,, and W. B. Martin, Cholestipol hydrochloride in hypercholesterolemic patients-effect on serum cholesterol and mortality,J.Chron.Dis 31: 5 (1978)

    Article  Google Scholar 

  30. P. T. Kuo, K. Hayase, J. B. Kostis, and A. E. Moreyra, Use of combined diet and colestipol in long-term (7-7.5 years) treatment of patients with type II hyperlipoproteinemia,Circulating 59: 199 (1979)

    Google Scholar 

  31. G. Crepaldi, R. Fellin, G. Baggio, and E. Manzato, Drug treat¬ment of primary hyperlipemias.Atherosclerosis Review 7: 203 (1980)

    Google Scholar 

  32. G. Briani, G. Crepaldi, Le diete ipolipidemizzanti. Giorn.Arteriosclerosi 1: 147 (1976)

    Google Scholar 

  33. J. L. Goldstein, M. S. Brown, The low density lipoprotein pathway and its relation to atherosclerosis,Ann.Rev.Biochem 46: 897 (1977)

    Article  Google Scholar 

  34. T. Gordon, W. P. Castelli, M. C. Hjortland, W. Kannell, and T.R. Dawber, High density lipoprotein as a protective factor against coronary heart disease,Am.J.Med 62: 707 (1977)

    Article  Google Scholar 

  35. J. R. Ryan, and A. Jain, The effect of Colestipol or Cholestiramine on serum cholesterol and triglycerides in long term controlled study,J.Clin.Pharmacol. New Drugs, 12: 268 (1972)

    Google Scholar 

  36. R. Fellin, G. Briani, P. Balestrieri, G. Baggio, M. R. Baiocchi, and G. Crepaldi, Long term effects of colestipol (U - 26, 597A) on plasma lipids in familial type II hyperbetalipoproteinemia,Atherosclerosis 22: 431 (1975)

    Article  Google Scholar 

  37. R. Fellin, G. Baggio, G. Briani, M. R. Baiocchi, E. Manzato, G. Baldo, and G. Crepaldi, Long term trial with colestipol plus clofibrate in familial hypercholesterolemia,Atherosclerosis 29: 241 (1978)

    Article  Google Scholar 

  38. R. J. Havel, and J. P. Kane, Drug and lipid metabolism.,Ann.Rew. Pharmacol 13: 287 (1973)

    Article  Google Scholar 

  39. S. M. Grundy, E. H. Ahrens, and G. Salen, Mechanism of action of clofiby°ate on cholesterol metabolism in patients with hyperlipidemia,J.Lipid Res. 13: 531 (1972)

    Google Scholar 

  40. G. Crepaldi, R. Fellin, and G. Briani, Human hyperliprotienemia. Principles and methods, in: “.Advances in experimental medicine and Biology,”R. Fumagalli, G. Ricci, S. Gorini, eds., Plenum Press, New York (1973)

    Google Scholar 

  41. G. Crepaldi, D. Fedele, R. Fellin, and G. Briani, Long term clofibrate treatment in familial hyperlipoproteinemias, in: “Atherosclerosis IV. Proceedings of the Fourth International Symposium on Atherosclerosis, West Berlin, Germany, October 24-28 1973,” G: Schettler, and A. Weizel, eds., Springer Verlag, New York (1974)

    Google Scholar 

  42. M. F. Oliver, J. A. Heady, N. Morris, and J. Cooper, Cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow up,Lancet 2: 379 (1980)

    Google Scholar 

  43. W. B. Parsons Jr., Use of nicontinic acid to reduce serum lipids levels,J.Am.Geriat.Soc. 10: 850 (1962)

    Google Scholar 

  44. L. A. Carlson, L. Oro, and J. Ostman, Effect of a single dose of nicotinic acid on plasma lipids in patients with hyperlipoproteinemia,Acta Med.Scand 183: 457 (1968)

    Article  Google Scholar 

  45. G. Briani, G. Valerio, R. Fellin, M. R. Baiocchi, G. Baggio, G. Baldo, E. Manzato, F. Beccaro, and G. Crepaldi, Trattamento delle iperlipoproteinemie primitive tipo Ha e IIb con l’associazione Clofirato + Xantiol/icoltinato,Giorn.Arterioscl. 5: 61 (1980)

    Google Scholar 

  46. R. L. Searcy, D. A. Hungerford, and M. Y. Lowe, Effects of dextrothyroxine on serum lipoproteins and cholesterol levels, Curr.Ther.Res 10: 177 (1968)

    Google Scholar 

  47. J. Stamler, M. Best, and J. D. Turner, The status of hormonal therapy for the primary and secondary prevention of athero¬sclerotic coronary heart disease,Prog.Cardiovasc.Dis 6: 220 (1963)

    Article  Google Scholar 

  48. G. Bagg o, G. Briani, R. Fellin, S. Martini, M. R. Baiocchi, and G. Crepaldi, Effect of Tiadenol on the concentration and composition of serum lipoproteins in familial hypercholesterolemias,Artery 5: 486 (1979)

    Google Scholar 

  49. G. Crepaldi, G. Briani, U. Senin, U. Montaguti, A. Capurso, and A. Bondioli, Multicenter trial with tiadenol in primary hyperlipidemias, in: “International Conference on Atherosclerosis, Milan Italy, November 1977, ” L. A. Carlson, R; Paoletti, and G. Weber, eds., Raven Press, New York (1978)

    Google Scholar 

  50. G. Crepaldi, R. Fellin, G. Baggio, and E. Manzato, Effect on lipid, lipoprotein and apoprotein levels of different hypolipidemic agents in type II hyperlipoproteinemia, in: “Drugs Affecting Lipid Metabolism,” R. Fumagalli, D. Kritchevsky, and R. Paoletti, eds., Elsevier, (1980)

    Google Scholar 

  51. J. Rouffy, C. Dreux, Y. Goussault, R. Dakkak, and F. J. Renson, Antilipidemic Drugs. Part 5: Evaluation of the hypolipidemic effect of LF-178 in 191 patients affected by the atherogenic form of endogenous hyperlipoproteinemia (types IIa, IIb, III, and IV),Arzneim Forsch 26: 901 (1976)

    Google Scholar 

  52. CR. Sirtori, E. Tremoli, M. Sirtori, F. Conti, and R.,Paoletti, Treatment of hypertriglyceridemia with Metformin: effectiveness and analysis of results, Atherosclerosis 26: 583 (1977).

    Article  Google Scholar 

  53. J. W. Barnhart, J. A. Sefranka, and D. D. McIntosh, Hypocholesterolemic effect of 4.4 (isopropydenedithio), bis (2.6-di-t¬buthylphenol) (probucol), Am.J.Clin.Nutr 23: 1229 (1970)

    Google Scholar 

  54. J. Nicholson, P. S. Gartside, M. Siegel, W. Spencer, P. M, Steiner, and C. J. Glueck, Lipid and lipoprotein distributions in octo- and nonagenarians,Metabolism 28: 51 (1979)

    Article  Google Scholar 

  55. R. Fellin, E. Manzato, F. Bernard, G. Valerio, M. R. Baiocchi, S. Martini, D. Tempesta, and G. Crepaldi, Fattori di rischio dell’arteriosclerosi periferica. Ruolo Belle lipoproteine ad alta densita (HDL),Giorn.Gerontol. 8: 465 (1981)

    Google Scholar 

  56. H. A. Eder, and L. J. Gidez, Symposium on lipid disorder, Med.Clinics N.Amer. 66: 431 (1982)

    Google Scholar 

  57. T. Gordon, W. B. Kannell, and W. P. Castelli, Lipoprotein, cardiovascular disease and death,Arch.Intern.Med. 141:1128 (1981):

    Google Scholar 

  58. R. Fellin, R. Brentari, G. Valerio, S. Martini, E. Manzato, G. Baggio, A. Meggio, R. Mezzena, and G. Crepaldi, Studio dei fattori di rischio di TIA i ICTUS in uno popolazione geriatrica, Giorn. Gerontol.11:805 (1982)

    Google Scholar 

  59. J. Schneider, High-density lipoproteins and peripheral vascular disease in octo- and nonagenarians,J.Am.Geriat.Soc. 28: 215 (1980)

    Google Scholar 

  60. P. Roschlau, E. Bernt, and W. Gruber, IX Congresso Intern. Chimica Clinica, Toronto 1975. Estratto n. 1 P. Trinder,Ann.Clin.Biochem 6: 24 (1969)

    Google Scholar 

  61. A. W. Wahlefeld in H. V. Bergmeyer: Methoden der enzymatischen Analyse. 30 Ed. Vol. II: 1878, Verlag Chemie Weinheim (1974)

    Google Scholar 

  62. A. Pagnan, R. Fellin, and G. Crepaldi, Studio elettroforetico delle lipoproteine plasmatiche su agarosio nei-soggetti normali ed in diverse condizioni morbose,Acta.Med.Patav 31: 71 (1971)

    Google Scholar 

  63. G. C. Descovich, S. Rimondi, Z. Sangiorgi, A. Gaddi, M. S. Benassi, C. I. Cordaro, G. Copparoni, G. Cavallo, N. Trivelli, C. Ceredi, G. Dalmonte, A. Dormi, P. Perini, G. L. Magri, L. Aluigi, G. Mannino, and S. Lenzi, Lo studio di Brisighella: i fattori di rischio cardiovascolare nella popolazione sopra i 60 anni. Corso di aggiornamento sulla cardiopatia ischemica, Chieti 1981, S. Lenzi, F. Cuccurullo, P. Puddu, F. Possati, eds., Compositori, Bologna (1981)

    Google Scholar 

  64. Y. Goto, Hyperlipemia and atherosclerosis in Japan,Atherosclerosis 36: 341 (1980)

    Article  Google Scholar 

  65. W. B. Kannel, T. Gordon, and T. R. Dawber, Role of lipids in the development of brain infarction: the Framingham Study,Stroke 5: 679 (1974)

    Article  Google Scholar 

  66. S. Buzzolo, P. Naliato, E. Tomat, S. Martini, R. Fellin, and G. Crepaldi, Fattori di rischio di infarto del miocardio nell’anziano,Giorn.Gerontol 30: 287 (1982)

    Google Scholar 

  67. D. Cucinotta, M. Mancini, G. Soncini, and M. Passeri, II Tiade¬nolo nella terapia degli stati dislipidemici in senescenza,Giorn.Gerontol 25: 389 (1977)

    Google Scholar 

  68. A. M. Lees, and R. S. Lees, “Handbook of Drug Therapy,” Miller and Greenblatt, eds., Elsevier, New York (1979):

    Google Scholar 

  69. R. I. Levy, “The Pharmacological Basis of Therapeutics,” Goodman and Gilman, eds., MacMillan, New York (1980)

    Google Scholar 

  70. J. P. Kane, and M. J. Malloy, Symposium on lipid disorders,Med.Clinics N.Amer 66:537 (1982)

    Google Scholar 

  71. W. E. Connor, and S. L. Connor, Symposium on lipid disorders,Med. Clinics N. Amer 66: 485 (1982)

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Clinical Medicine, University of Padova, Italy

    R. Fellin & G. Crepaldi

  2. Geriatric Hospital, Padova, Italy

    G. Valerio, T. Beroldin, A. L. Angelini & O. De Candia

Authors
  1. R. Fellin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Valerio
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T. Beroldin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. L. Angelini
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. O. De Candia
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G. Crepaldi
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Institute of Internal Medicine and Geriatrics, University of Palermo, Palermo, Italy

    G. Barbagallo-Sangiorgi

  2. School of Medicine, University College London, London, England

    A. N. Exton-Smith

Rights and permissions

Reprints and permissions

Copyright information

© 1984 Plenum Press, New York

About this chapter

Cite this chapter

Fellin, R., Valerio, G., Beroldin, T., Angelini, A.L., De Candia, O., Crepaldi, G. (1984). Plasma Lipids and Frequency of Hyperlipidaemia in the Elderly: Indications and Cost/Benefit Ratio of Hypolipidaemic Treatment. In: Barbagallo-Sangiorgi, G., Exton-Smith, A.N. (eds) Aging and Drug Therapy. Ettore Majorana International Science Series. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-2791-2_18

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-2791-2_18

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4612-9721-5

  • Online ISBN: 978-1-4613-2791-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation